Loading
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$3.29
+$0.06 · +1.86%
SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat human smallpox, a condition caused by the variola virus. Furthermore, the company has forged a strategic collaboration with Cipla Therapeutics. This partnership aims to ensure ongoing innovation and accessibility of antibacterial treatments, particularly those designed to counter biothreats. Founded in 1995, SIGA Technologies' corporate headquarters are located in New York, New York.
Previous close
$3.29
+$0.06 · +1.86%
Regular session · ET · Market data may be delayed.
SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat human smallpox, a condition caused by the variola virus. Furthermore, the company has forged a strategic collaboration with Cipla Therapeutics. This partnership aims to ensure ongoing innovation and accessibility of antibacterial treatments, particularly those designed to counter biothreats. Founded in 1995, SIGA Technologies' corporate headquarters are located in New York, New York.
Day range
Current $3.29
52-week range
Current $3.29
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
82
Deep Value
Sentiment
72
Bullish
Risk
61
High Risk
Momentum
21
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat human smallpox, a condition caused by the variola virus. Furthermore, the company has forged a strategic collaboration with Cipla Therapeutics. This partnership aims to ensure ongoing innovation and accessibility of antibacterial treatments, particularly those designed to counter biothreats. Founded in 1995, SIGA Technologies' corporate headquarters are located in New York, New York.
Day range
Current $3.29
52-week range
Current $3.29
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 94.6M USD | 138.72M USD | 139.92M USD | 110.78M USD | 133.67M USD |
| Cost of goods sold | 29.7M USD | 31.29M USD | 17.83M USD | 10.43M USD | 16.6M USD |
| Gross profit | 64.87M USD | 107.43M USD | 122.09M USD | 100.34M USD | 117.07M USD |
| Research and development | 6.53M USD | 12.31M USD | 16.43M USD | 22.53M USD | 9.94M USD |
| Selling, general, and administrative | 3.13M USD | 25.14M USD | 22.04M USD | 35.12M USD | 18.03M USD |
| Operating expenses | 41.17M USD | 37.45M USD | 38.47M USD | 57.64M USD | 27.98M USD |
| Interest income | 6.68M USD | — | — | — | — |
| Depreciation and amortization | 562.61K USD | 538.42K USD | 538.29K USD | 517.64K USD | 522.37K USD |
| Operating income | 23.7M USD | 69.98M USD | 83.62M USD | 42.7M USD | 89.09M USD |
| Net income | 23.3M USD | 59.21M USD | 68.07M USD | 33.9M USD | 69.45M USD |
Company facts updated Sep 7, 2026.
Recent quarterly results
Recent quarterly results
Cash distributions grouped by calendar year; partial years are marked.
$0.60
2025 complete year+33.3% since 2022
2026 partial: $0.60
$0.45
2,022
$0.45
2,023
$0.60
2,024
$0.60
2,025
$0.60
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Apr 7, 2026 | $0.60Special | Apr 7, 2026 | Apr 23, 2026 |
Dividend | Apr 29, 2025 | $0.60Special | Apr 29, 2025 | May 15, 2025 |
Dividend | Mar 25, 2024 | $0.60Special | Mar 26, 2024 | Apr 11, 2024 |
Dividend | May 15, 2023 | $0.45Special | May 16, 2023 | Jun 1, 2023 |
Dividend | May 16, 2022 | $0.45Special | May 17, 2022 | Jun 2, 2022 |
Ex-dividend Apr 7, 2026
$0.60
Special
Record Apr 7, 2026 · Payment Apr 23, 2026
Ex-dividend Apr 29, 2025
$0.60
Special
Record Apr 29, 2025 · Payment May 15, 2025
Ex-dividend Mar 25, 2024
$0.60
Special
Record Mar 26, 2024 · Payment Apr 11, 2024
Ex-dividend May 15, 2023
$0.45
Special
Record May 16, 2023 · Payment Jun 1, 2023
Ex-dividend May 16, 2022
$0.45
Special
Record May 17, 2022 · Payment Jun 2, 2022
Funds reporting this stock among their holdings, ordered by reported position size.
Avantis U.S. Small Cap Value ETFAVUV4.57M0.01%31.49B USD0.25%$126.93+0.52%
Vanguard Morningstar Total Stock Market ETFVTI3.94M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 ETFIWM3.6M0.00%79.88B USD0.19%$296.01+0.28%
Vanguard Extended Market ETFVXF1.61M0.00%93.7B USD0.05%$242.66+0.14%
iShares Russell 2000 Value ETFIWN1.26M0.01%14.47B USD0.24%$224.62+0.40%
U.S. Micro Cap Portfolio ETFDFMC826.39K0.01%7.81B USD0.43%$60.36+0.60%
Vanguard Russell 2000 ETFVTWO782.04K0.00%17.4B USD0.06%$119.62+0.25%
Schwab U.S. Small-Cap ETFSCHA634.98K0.00%22.56B USD0.03%$34.55+1.01%Avantis U.S. Small Cap Value ETFAVUVVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNU.S. Micro Cap Portfolio ETFDFMCVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
